Compare Incyte Corporation (INCY) vs OneSpan Inc (OSPN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs OneSpan Inc — how do they compare? Incyte Corporation trades at $117.76 (market cap $23.11B), while OneSpan Inc trades at $15.34 (market cap $575.37M). The key difference: Incyte Corporation is far larger — about 40.2× OneSpan Inc's market cap, and OneSpan Inc pays a 3.35% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | OSPN | |
|---|---|---|
Market Cap | $23.11B | $575.37M |
Sector | Health | Technology |
52-Week High | $118.52 | $16.32 |
52-Week Low | $67.38 | $10.15 |
Enterprise Value | $19.13B | $533.57M |
Dividend Yield | — | 3.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
OneSpan (OSPN) trades at $15.51, showing modest daily gains of 0.26% with strong technical momentum indicated by bullish moving averages. The company demonstrates robust profitability with a 28.47% net income margin and consistent earnings beats in recent quarters. Recent corporate developments include a $0.13 dividend payment and upcoming Q2 2026 earnings announcement on August 4, 2026.
The stock presents attractive valuation metrics with a P/E of 8.55 and strong analyst support (66.7% buy ratings), though current price exceeds the $13.50 consensus target. Key risks include negative cash flow trends and competitive pressures in the cybersecurity sector. Earnings growth remains the primary catalyst for further upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About OneSpan Inc
OneSpan Inc. is a global leader in providing digital agreement security solutions. The company's platform helps organizations, primarily in the financial services sector, to secure their digital agreements and transactions, including e-signatures, multi-factor authentication, and transaction monitoring. OneSpan's technology is focused on protecting customers from fraud and meeting regulatory compliance requirements in a digital-first environment.
Read more on OSPN →
